Clinical trials are essential for generating evidence on the safety and efficacy of new medicines, devices, and treatment protocols. Iraq has a long tradition of clinical research within its medical institutions and is increasingly being considered as a clinical trial destination by international sponsors, given its population size, diverse disease profile, and capable academic medical centers. The legal and ethical framework for clinical research is anchored in the Public Health Law No. 89 of 1981, ministerial instructions, and standards of Good Clinical Practice (GCP) that Iraq has adopted in line with international norms.
Regulatory authority over clinical trials rests primarily with the Ministry of Health, acting through the Iraqi Drug Control Department (IDCD) and dedicated committees that review trial protocols. No clinical trial may lawfully commence without express prior approval from the Ministry, regardless of whether the trial is sponsored by a foreign pharmaceutical company, an academic institution, or a government agency. In parallel with regulatory authorization, ethical approval must be obtained from a competent ethics committee which may be an institutional review board attached to a hospital or university, or a national ethics committee established by the Ministry of Health. The committee reviews the protocol, informed consent forms, investigators’ qualifications, the suitability of the trial site, indemnity and insurance arrangements, and the procedures for adverse event reporting.
Protocol and Its Approval
The protocol is the central document of a clinical trial, and it must meet defined standards in terms of clarity, scientific rigor, and ethical justification. It should state the trial’s objectives, design, methodology, statistical considerations, ethical justification, risks and benefits, inclusion and exclusion criteria, dosing and safety monitoring, and criteria for discontinuation. Trials investigating new chemical entities, biologics, or advanced therapies are typically subject to additional scrutiny, and sponsors should expect a more extended dialogue with the regulator in these cases.
Informed Consent
Informed consent is a cornerstone of the legal framework, not merely a procedural requirement. Written consent from each participant or from a legally authorized representative where the participant lacks capacity must be obtained before any trial-related procedures are performed. The consent process must be conducted in a language the participant understands, with adequate time for questions, free of any coercion or undue inducement. Special protections apply to vulnerable populations, including children, pregnant women, prisoners, and those with diminished capacity to consent. The quality of the consent process is the first thing an ethics committee will examine when concerns arise about a trial, and inadequate consent is one of the most common grounds for adverse findings.
Investigational Products
Investigational products require specific import permits in addition to the trial approval itself. The sponsor must apply to the Ministry of Health for permits covering the investigational product, comparator medications, and any rescue medications. These permits include conditions on storage, accountability, and destruction or return of unused material at the end of the trial. Cold chain investigational products require additional logistics planning. Sponsors with experience in other regional markets sometimes underestimate the lead time required to bring investigational supplies through Iraqi customs, and we routinely recommend building generous margins into the project timeline at this stage.
Sponsor Responsibilities
Sponsor responsibilities under the Iraqi framework are substantial and include selection of qualified investigators and sites, monitoring of trial conduct, data management, pharmacovigilance, reporting of serious adverse events, compliance with the protocol and applicable laws, maintenance of trial master files, and cooperation with inspections by the Ministry. Foreign sponsors generally appoint a local representative or contract research organization (CRO) to act on their behalf in Iraq, and that representative shoulders much of the practical compliance burden. The contractual arrangement between sponsor and local representative is therefore one of the more important documents in any Iraqi clinical trial.
Investigators carry their own legal obligations: conducting the trial in accordance with the protocol, maintaining accurate trial records, ensuring proper informed consent, reporting adverse events promptly, and cooperating with monitoring and audit activities. Investigators must have appropriate qualifications and adequate resources to conduct the trial, and they must declare any conflicts of interest. The relationship between sponsor, CRO, investigator, and site is best set out clearly in agreements that anticipate the practical issues that arise during a multi-year trial.
Adverse Event Reporting
Adverse event reporting follows defined timelines. Fatal or life-threatening events are typically reported within 24 hours; other serious adverse events within 7 or 15 days depending on classification. The sponsor must submit periodic safety reports and inform the regulator of any safety signals that may affect the risk-benefit assessment. Adequate pharmacovigilance systems are not optional, they are a precondition for the conduct of any clinical trial in Iraq.
Insurance and Compensation
The sponsor must arrange clinical trial insurance covering injury or death attributable to the trial, on terms acceptable to the Ministry of Health and the ethics committee. Compensation arrangements should be clearly described in the informed consent document, and the principles of no-fault compensation are increasingly applied for trial-related injuries. Personal data of participants must be handled in accordance with applicable legal standards and the principles of confidentiality; where data is transferred outside Iraq, appropriate safeguards should be in place.
Trial Completion
On completion of the trial, the sponsor must submit a final report to the Ministry of Health and ensure that unused investigational product is destroyed or returned per the conditions of the import permit. Publication of results, positive and negative, is increasingly expected as a matter of scientific and ethical practice, and Iraqi regulators are aligned with the international trend in this regard.
How We Can Help
Etihad Law Firm advises sponsors, CROs, and academic institutions on the full regulatory and contractual aspects of clinical trials in Iraq, including approvals, site agreements, investigator contracts, pharmacovigilance, and dispute resolution. The framework is workable for well-prepared sponsors, and we routinely help clients navigate it from initial feasibility through to study close-out.